JAK2 and myeloid leukemia: Furthermore, MLKL attenuated colon inflammation and colitis tumorigenesis via suppression of inflammatory responses [17], inhibited intestinal tumorigenesis by suppressing the IL-6/JAK2/STAT3 pathway [61] and promoted cellular differentiation in myeloid leukemia by facilitating the release of G-CSF [18].